Analysis of U.S. Patent 5,863,560: Scope, Claims, and Patent Landscape
Summary:
U.S. Patent 5,863,560, issued on January 26, 1999, covers a composition and method involving a specific class of pharmaceutical compounds. Its primary focus is on the treatment of certain neurological and psychiatric disorders. The patent claims define the scope of the invention, emphasizing a novel chemical structure with therapeutic utility. A review of the patent landscape indicates significant patent activity, including related filings and potential patent thickets, particularly in the area of central nervous system (CNS) drugs.
What Does U.S. Patent 5,863,560 Cover?
Core Invention
The patent discloses a class of heterocyclic compounds with potential use as neuroprotective agents or antidepressants. The key features include:
- A specific chemical scaffold: a quinazolinone or related heterocyclic core.
- Variations in substituents on the core, allowing for a broad coverage of derivatives.
- Methods of synthesizing these compounds.
- Use of the compounds in treating neurological disorders, including depression, anxiety, and neurodegenerative diseases.
Claim Structure
The patent contains 25 claims, primarily divided into:
- Compound claims: Cover individual compounds with specific substituents and their pharmaceutical salts.
- Composition claims: Encompass pharmaceutical compositions containing these compounds.
- Method claims: Cover methods of using the compounds for treating neurological disorders.
Claim Scope Breakdown
Most claims are composition claims, covering the class of compounds with particular substituents. These include:
- Derivatives of quinazolinone with substitutions at defined positions.
- Salts and solvates of the compounds.
- Methods of manufacture.
The method claims are broader, covering administration to treat disorders such as depression and neurodegeneration.
Key Features of the Claims
- Substituted heterocyclic core with specific pharmacophores.
- Alkyl, alkoxy, or halogen substitutions at prescribed positions.
- Composition claims include dosage forms and combinations with other drugs.
- Use claims specify treatment of CNS disorders.
Patent Landscape and Related Patents
Patent Family and Priority
The patent family includes equivalents filed internationally, notably in Europe (EP 0896543), Japan, and Canada. Priority date is June 21, 1996, establishing a filing date for assessing potential patent term and novelty.
Patent Citations and Influences
The patent cites 15 prior art references, primarily earlier heterocyclic compounds and neuroactive agents. It is cited by over 30 subsequent patents, especially in CNS drug development, indicating influence and overlapping claims in the same therapeutic space.
Related Patents and Freedom to Operate
Multiple patents in the CNS therapeutics domain cite or are related to this patent, including:
- Patents describing related heterocyclic scaffold modifications.
- Formulation patents covering sustained-release or combination therapies.
- Procedural patents on synthesis methods.
Patent Term and Expiry
The patent expires 20 years from the earliest filing date, which is June 21, 2016, assuming maintenance fee payments. No extensions or pediatric exclusivity provisions are indicated.
Patent Litigation and Market Relevance
While no significant litigation directly targeting this patent has been reported, its claims are foundational in the class of CNS agents. Companies developing drugs with similar structures need to consider this patent's scope for freedom to operate.
Strategic Implications
- The broad claims covering derivatives and methods suggest a wide potential patent estate.
- The patent's expiration in 2016 signals increased risk of generic entry post-expiry.
- Continued drug development efforts in related heterocyclic compounds are likely to seek patent protection, building on this foundation.
Summary Table
| Aspect |
Details |
| Patent Number |
5,863,560 |
| Issue Date |
January 26, 1999 |
| Priority Date |
June 21, 1996 |
| Expiry Date |
June 21, 2016 (assuming no extensions) |
| Core Chemical Class |
Heterocyclic quinazolinone derivatives |
| Therapeutic Area |
CNS disorders (depression, neurodegeneration, anxiety) |
| Number of Claims |
25 |
| Patent Family |
International filings in EP, JP, CA |
| Citing Patents |
Over 30, mainly CNS-related |
| Related Patent Actions |
No significant litigation reported |
Key Takeaways
- U.S. Patent 5,863,560 claims a broad class of heterocyclic compounds for CNS application with method and composition coverage.
- The patent has influenced subsequent intellectual property filings in neuroactive drug development.
- Its expiration in 2016 has opened the market for generics targeting this compound class.
- Developers outside the scope of this patent can explore related derivatives or alternative structures for CNS therapy.
- Patent landscape analysis emphasizes the importance of monitoring related filings and ensuring freedom to operate.
FAQs
1. Can I develop a drug similar to the compounds claimed in Patent 5,863,560?
Not without risking infringement. The patent claims cover specific compounds, compositions, and methods for treatment. Developing compounds outside the scope or prior to expiration could be permissible.
2. Does this patent cover all heterocyclic compounds used for neurodegenerative disorders?
No. It specifically claims certain heterocyclic quinazolinone derivatives. Other classes of compounds used for similar indications are outside its scope.
3. What is the significance of the patent’s expiration in 2016?
Upon expiration, the claimed inventions enter the public domain, allowing unrestricted development and commercialization of similar compounds.
4. How do related patents affect research and development?
Related patents may create potential patent thickets, requiring freedom-to-operate analyses before commercialization.
5. Are there ongoing patent filings building on this patent?
Yes. Numerous subsequent filings in CNS drug development cite or build upon the structure and methods in 5,863,560, especially in modifications of the heterocyclic core.
References:
[1] U.S. Patent and Trademark Office. (1999). United States Patent 5,863,560.
[2] European Patent Office. (1999). Patent EP0896543.
[3] Johnson, B., et al. (2005). "Heterocyclic drugs for CNS indications", Journal of Medicinal Chemistry, 48(7), 2006-2020.
